Hormonal
Insulin resistance and hypertension are evolutionary adaptations (thrifty genotype) designed to conserve energy and sodium during famine, infection, or stress, which become maladaptive in modern environments characterized by caloric and sodium abundance.
Recognize that insulin resistance and high blood pressure are not just random errors but evolved survival mechanisms. In a modern world of abundant food and salt, these mechanisms overcompensate. Management requires actively counteracting these ancient drives through lifestyle choices that mimic the 'scarcity' conditions (e.g., physical activity, controlled sodium intake) that originally selected for these traits.
The human propensity for insulin resistance and hypertension is a product, at least in part, of our evolutionary history. Adaptation to ancient lifestyle characterized by a low sodium, low-calorie food supply and physical stress to injury response has driven our evolution to shape and preserve a thrifty genotype, which is favorite with energy-saving and sodium conservation.
Why this rating
The paper is a review of evolutionary hypotheses and observational associations, lacking direct experimental validation of the evolutionary timeline in humans.
Source
Link between insulin resistance and hypertension: What is the evidence from evolutionary biology?
Ming-Sheng Zhou et al. · Diabetology & Metabolic Syndrome · 2014
DOI 10.1186/1758-5996-6-12
More from this paper
- Chronic low-grade inflammation, driven by obesity and excess nutrient intake, is a primary mechanistic link that causes both insulin resistance and hypertension by impairing insulin signaling and promoting vasoconstriction.Good
- Sodium retention is an evolutionarily conserved mechanism linked to insulin resistance, where insulin promotes sodium reabsorption in the kidney, and high salt intake exacerbates hypertension in salt-sensitive individuals with insulin resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →